vorasidenib
servier
['vorasidenib', 'indigo', 'servier']
servier eyes approval for vorasidenib after positive phase iii results in idh1/2-mutant glioma. vorasidenib increased progression-free survival and time to next treatment versus placebo in results from the indigo trial, presented at asco this week. 